WUXIDAR4
Dead / Abandoned — Abandoned — no statement of use filed (as of 16 Jan 2023)
What this means for you
This application is over — abandoned 16 Jan 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90182832
- Mark type
- Design + words
- Filed
- 15 Sept 2020
- Published for opposition
- 20 Apr 2021
- Abandoned
- 16 Jan 2023
- Attorney of record
- Michael T. Smith
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Drugs for medical purposes, namely, anticancer drugs; Biological preparations for medical purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Medicines for human purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Biochemical medicines for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Antibody drug for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Multispecific antibody for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Multispecific antibody format for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Medicines for veterinary purposes for treatment of canine disease; Biological preparations for veterinary purposes for treatment of canine disease
- Class 040 — Treatment of materials: Biomanufacturing for others, namely, manufacturing of biopharmaceuticals using biological organisms in the manufacturing process; Custom manufacture of biopharmaceuticals by pharmaceutical compounders; Manufacturing services for others in the field of biopharmaceuticals
- Class 042 — Scientific and technological services: Biomedical research services; Development of pharmaceutical preparations and medicines; Drug discovery services; Laboratory research services relating to pharmaceuticals; Pharmaceutical drug development services; Pharmaceutical research services; Product development for others; Product quality testing services; Product safety testing services; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of new products for others; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy
Owner
- WuXi Biologics Co., Ltd., Wuxi, Jiangsu, CN
- WuXi Biologics Co., Ltd., Wuxi, Jiangsu, CN
Prosecution history
- 17 Jan 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 16 Jan 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 14 Jun 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jun 2022 — SOU EXTENSION 2 GRANTED
- 10 Jun 2022 — SOU EXTENSION 2 FILED
- 10 Jun 2022 — SOU TEAS EXTENSION RECEIVED
- 16 Dec 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Dec 2021 — SOU EXTENSION 1 GRANTED
- 14 Dec 2021 — SOU EXTENSION 1 FILED
- 14 Dec 2021 — SOU TEAS EXTENSION RECEIVED
- 15 Jun 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 Apr 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 Apr 2021 — PUBLISHED FOR OPPOSITION
- 31 Mar 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Mar 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER